Frankfurt - Delayed Quote EUR

Context Therapeutics Inc. (6K9.F)

Compare
0.7450
0.0000
(0.00%)
At close: 8:07:20 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Martin A. Lehr Co-Founder, President, CEO & Director 642.97k -- 1984
Ms. Jennifer Minai-Azary CFO & Treasurer 480.87k -- 1978
Mr. Alex C. Levit Esq. Chief Legal Officer & Corporate Secretary 461.5k -- 1979
Mr. Christopher Beck M.B.A. Senior Vice President of Operations -- -- --
Dr. Claudio Dansky Ullmann M.D. Chief Medical Officer -- -- --

Context Therapeutics Inc.

2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
267 225 7416 https://www.contexttherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
5

Description

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Context Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers